| CAS NO: | 439085-51-5 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| Cas No. | 439085-51-5 |
| 别名 | 3-乙氧基-6-(2-(1-(6-甲基哒嗪-3-基)哌啶-4-基)乙氧基)苯并[D]异恶唑,BTA798 |
| Canonical SMILES | CCOC1=NOC2=CC(OCCC3CCN(C4=CC=C(C)N=N4)CC3)=CC=C21 |
| 分子式 | C21H26N4O3 |
| 分子量 | 382.5 |
| 溶解度 | Chloroform: 10 mg/ml,DMF: 1 mg/ml |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Vapendavir is a capsid-binding antiviral agent.1,2It binds to a pocket in the human rhinovirus (HRV) strain HRV2 VP1 capsid protein and inhibits the cytopathic effects of HRV2 and HRV14 in HeLa Ohio cells (EC50s = 1 and 5 ng/ml, respectively), as well as in a panel of 39 HRV clinical isolates (median EC50= 7.3 ng/ml).1Vapendavir inhibits replication in a panel of 21 enterovirus 71 (EV71) isolates with an average EC50value of 0.7 μM.2 1.Feil, S.C., Hamilton, S., Krippner, G.Y., et al.An orally available 3-ethoxybenzisoxazole capsid binder with clinical activity against human rhinovirusACS Med. Chem. Lett.3(4)303-307(2012) 2.Tijsma, A., Franco, D., Tucker, S., et al.The capsid binder vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replicationAntimicrob. Agents Chemother.58(11)6990-6992(2014) |
m.cnreagent.com